Talquetamab

塔奎妥单抗

Report date: 2026/03/19 17:24:02
First In Class

Base Information

Drug NameTalquetamab
Drug Alias NameTalquetamab-tgvsGPRC5D/CD3-duobody-antibodyTALVEY拓立珂JNJ-7564 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionAnti-GPRC5DT-cell surface glycoprotein CD3 epsilon chain modulators
TargetsG-protein coupled receptor family C group 5member DT-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsHematologic NeoplasmsMultiple Myeloma
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2023/08/09
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative MedicineGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson KkFisher BioservicesJohnson & Johnson (China) Investment Ltd +[8] 
Inactive CompaniesJohnson & Johnson Pharmaceutical LtdJanssen Pharmaceuticals IncJanssen Pharmaceutical Kk +[4] 
Active IndicationsHematologic NeoplasmsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG